XoNovo

Company Overview

Snapshot

Founded in August 2013 by Kenneth Hensley and Rafi Gidron, XoNovo operated with 11–50 employees. The company ceased operations in September 2019. In January 2015, XoNovo secured funding from FutuRx.

Business overview

XoNovo was a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function in various neurodegenerative diseases. The company's core technology involved a novel approach of selective modulation of autophagy and axonal transport machinery in neurons. Its lead drug candidate, XN001, was being developed for Batten disease (BD), also known as neuronal ceroid lipofuscinoses, a fatal neurodegenerative orphan disorder, and had shown promising results in models for Alzheimer's disease, glioblastoma, muscular dystrophy, and tuberous sclerosis. XoNovo operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the Pharmaceuticals market.

Company Intelligence Q&A

What was XoNovo's primary focus?

XoNovo was a preclinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to prevent the progressive loss of neuronal function across multiple neurodegenerative diseases.

When was XoNovo founded and by whom?

XoNovo was founded in August 2013 by Kenneth Hensley and Rafi Gidron.

What was the status of XoNovo's operations?

XoNovo ceased to operate in September 2019.

What was the lead drug candidate for XoNovo?

XoNovo's lead drug candidate was XN001, which was being developed for Batten disease (BD) and had shown promising results in various neurodegenerative disease models.